- The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization to Merck & Co Inc MRK and Ridgeback Biotherapeutics' molnupiravir (MK-4482) for COVID-19.
- The approval marks the first oral antiviral medicine authorized to treat mild-to-moderate COVID-19 in adults who have at least one risk factor for developing severe illness.
- In the U.K., Lagevrio is the planned trademark for molnupiravir.
- Molnupiravir application is under review in the U.S. and Europe.
- Merck is actively working to submit applications to other regulatory agencies around the world.
- Related: Merck, Ridgeback File For Emergency Use Nod For COVID-19 Antiviral.
- Price Action: MRK shares are up 2.19% at $90.62 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
